Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jennie H Best

Showing results (1-10 of 37) with videos related to

Pageof 4
Sort By:
Cancer|March 10, 2005
Cost utility in the United States of rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone for the treatment of elderly patients with diffuse large B-cell lymphomaJohn C Hornberger, Jennie H Best
Expert Review of Pharmacoeconomics & Outcomes Research|April 14, 2010
Economic evaluation of capecitabine as adjuvant or metastatic therapy in colorectal cancerJennie H Best, Louis P Garrison
Rheumatology and Therapy|January 8, 2020
Comparative Cost per Response for 4 Clinical Endpoints with Tocilizumab Monotherapy vs Adalimumab Monotherapy in a Head-to-Head Randomized Double-Blind Superiority Trial (ADACTA) in Patients with Rheumatoid ArthritisJennie H Best, Steven C Vlad, Jinglan Pei
Journal of Diabetes|August 30, 2014
Dynamic risk factors associated with non-severe hypoglycemia in patients treated with insulin glargine or exenatide once weeklySanjoy K Paul, David Maggs, Kerenaftali Klein, et al.
Cardiovascular Diabetology|January 25, 2015
The association of the treatment with glucagon-like peptide-1 receptor agonist exenatide or insulin with cardiovascular outcomes in patients with type 2 diabetes: a retrospective observational studySanjoy K Paul, Kerenaftali Klein, David Maggs, et al.
Rheumatology and Therapy|April 1, 2020
Real-World Persistence with Tocilizumab Compared to Other Subcutaneous Biologic Disease-Modifying Antirheumatic Drugs Among Patients with Rheumatoid Arthritis Switching from Another BiologicJennie H Best, Steven C Vlad, Lenore Tominna, et al.
Rheumatology and Therapy|February 23, 2018
Costs of Disease Relapses Among Individuals with Granulomatosis, with Polyangiitis, or Microscopic Polyangiitis in the United StatesAmanda M Kong, Gilwan Kim, Margaret Michalska, et al.
Journal of Diabetes|January 15, 2015
Comparison of trajectories of self-monitored glucose levels by hypoglycemia status over 52 weeks of treatment with insulin glargine or exenatide once weeklySanjoy K Paul, Julius Agbeve, David Maggs, et al.
Current Medical Research and Opinion|March 5, 2010
Patient reported outcomes in adults with type 2 diabetes on basal insulin randomized to addition of mealtime pramlintide or rapid-acting insulin analogsMark Peyrot, Richard R Rubin, William H Polonsky, et al.
Rheumatology and Therapy|October 28, 2019
Risk of Potential Glucocorticoid-Related Adverse Events in Patients with Giant Cell Arteritis: Results from a USA-Based Electronic Health Records DatabaseJennie H Best, Amanda M Kong, Sebastian Unizony, et al.
Pageof 4

Showing results (1-10 of 37) with videos related to

Sort By:
Pageof 4
Cancer|March 10, 2005
Cost utility in the United States of rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone for the treatment of elderly patients with diffuse large B-cell lymphomaJohn C Hornberger, Jennie H Best
Expert Review of Pharmacoeconomics & Outcomes Research|April 14, 2010
Economic evaluation of capecitabine as adjuvant or metastatic therapy in colorectal cancerJennie H Best, Louis P Garrison
Rheumatology and Therapy|January 8, 2020
Comparative Cost per Response for 4 Clinical Endpoints with Tocilizumab Monotherapy vs Adalimumab Monotherapy in a Head-to-Head Randomized Double-Blind Superiority Trial (ADACTA) in Patients with Rheumatoid ArthritisJennie H Best, Steven C Vlad, Jinglan Pei
Journal of Diabetes|August 30, 2014
Dynamic risk factors associated with non-severe hypoglycemia in patients treated with insulin glargine or exenatide once weeklySanjoy K Paul, David Maggs, Kerenaftali Klein, et al.
Cardiovascular Diabetology|January 25, 2015
The association of the treatment with glucagon-like peptide-1 receptor agonist exenatide or insulin with cardiovascular outcomes in patients with type 2 diabetes: a retrospective observational studySanjoy K Paul, Kerenaftali Klein, David Maggs, et al.
Rheumatology and Therapy|April 1, 2020
Real-World Persistence with Tocilizumab Compared to Other Subcutaneous Biologic Disease-Modifying Antirheumatic Drugs Among Patients with Rheumatoid Arthritis Switching from Another BiologicJennie H Best, Steven C Vlad, Lenore Tominna, et al.
Rheumatology and Therapy|February 23, 2018
Costs of Disease Relapses Among Individuals with Granulomatosis, with Polyangiitis, or Microscopic Polyangiitis in the United StatesAmanda M Kong, Gilwan Kim, Margaret Michalska, et al.
Journal of Diabetes|January 15, 2015
Comparison of trajectories of self-monitored glucose levels by hypoglycemia status over 52 weeks of treatment with insulin glargine or exenatide once weeklySanjoy K Paul, Julius Agbeve, David Maggs, et al.
Current Medical Research and Opinion|March 5, 2010
Patient reported outcomes in adults with type 2 diabetes on basal insulin randomized to addition of mealtime pramlintide or rapid-acting insulin analogsMark Peyrot, Richard R Rubin, William H Polonsky, et al.
Rheumatology and Therapy|October 28, 2019
Risk of Potential Glucocorticoid-Related Adverse Events in Patients with Giant Cell Arteritis: Results from a USA-Based Electronic Health Records DatabaseJennie H Best, Amanda M Kong, Sebastian Unizony, et al.
Pageof 4